| 翻訳と辞書 |
Immunocore
Immunocore is a privately owned British clinical-stage biotechnology company,〔 based in Oxfordshire, which researches and develops cancer treatments using T-cell receptors (TCRs).
==History==
Immunocore was founded in 2008 as a spinout of German Medigene AG who had acquired former Avidex in 2006, which was founded in 1999 as a spinout from the University of Oxford by Dr Bent Jakobsen.
In July 2013 GlaxoSmithKline paid ₤142 million for the rights to pre-clinical drugs they had developed which act against several targets that Immunocore had been working on. In June 2013 Immunocore had entered into a similar deal with Genentech, which, according to the deal, would earn Immunocore an initiation fee of between $10 million and $20 million for each lead program initiated by Genentech and in excess of $300 million in milestone payments for each target programme and significant tiered royalties. In January 2014 MedImmune - the global biologics research and development arm of AstraZeneca - announced the next oncology research collaboration and licensing agreement for Immunocore, who then was eligible to receive an upfront payment of $20 million and up to $300 million in development and commercial milestone payments for each target programme selected as well as significant tiered royalties if these programmes are successful.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Immunocore」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|